Table 2.
Characteristic and treatment of pediatric renal transplant patients (rDIABGRAFT).
| RT (n = 20) | RT HG positive (n = 11) | RT HG negative (n = 9) | |
|---|---|---|---|
| CHARACTERISTIC | |||
| Gender, man, n (%) | 13 (65.0) | 7 (63.6) | 6 (66.7) |
| Alive, n (%) | 19 (95.0) | 10 (90.9) | 9 (100.0) |
| Age of renal transplant, year, median (p25; p75) | 12.3 (9.3; 15.6) | 11.5 (10.4; 14.3) | 13.1 (5.1; 16.5) |
| [0–8], n (%) | 5 (25.0) | 2 (18.2) | 3 (33.3) |
| [9–18], n (%) | 15 (75.0) | 9 (81.8) | 6 (66.7) |
| Overweight/Obesity before transplant, n (%) | 4 (20.0) | 3 (27.3) | 1 (11.1) |
| Weight, SDS, median (p25; p75) | −0.9 (−2.0; −0.1) | −0.6 (−2.2; +0.0) | −1.1 (−1.9; −0.3) |
| Height, SDS, median (p25; p75) | −1.3 (−2.2; −0.6) | −2.1 (−2.5; −1.5) | −0.6 (−1.2; −0.4) |
| BMI, SDS, median (p25; p75) | −0.1 (−1.4; +0.7) | +0.3 (−1.0; +1.1) | −0.3 (−1.6; +0.2) |
| PERSONAL HISTORY | |||
| Other transplants (liver), n (%) | 3 (15.0) | 3 (27.3) | – |
| LT before RT, n (%) | 2 (10.0) | 2 (18.2) | – |
| LT the same day as RT, n (%) | 3 (15.0) | 3 (27.3) | – |
| Treatment before renal transplantation | |||
| Glucocorticoids, n (%) | 5 (25.0) | 4 (36.4) | 1 (11.1) |
| Immunosuppressors, n (%) | 4 (20.0) | 3 (27.3) | 1 (11.1) |
| Dialysis treatment, n (%) | 13 (65.0) | 6 (54.5) | 7 (77.8) |
| Hemodialysis, n (%) | 10 (50.0) | 6 (54.5) | 4 (44.4) |
| Peritoneal dialysis, n (%) | 9 (45.0) | 5 (45.5) | 4 (44.4) |
| TRANSPLANTATION AND TREATMENTS | |||
| Living donor for renal transplant, n (%) | 7 (35.0) | 3 (27.3) | 4 (44.4) |
| Father, n (%) | 2 (10.0) | – | 2 (22.2) |
| Mother, n (%) | 3 (15.0) | 1 (9.1) | 2 (22.2) |
| Friend, n (%) | 1 (5.0) | 1 (9.1) | – |
| Sister, n (%) | 1 (5.0) | 1 (9.1) | – |
| Immunosuppressive treatments post-transplant | |||
| Tacrolimus, n (%) | 20 (100.0) | 11 (100.0) | 9 (100.0) |
| Glucocorticoids, n (%) | 20 (100.0) | 11 (100.0) | 9 (100.0) |
| Patient treated until the end of the study, n (%) | 14 (70.0) | 7 (63.6) | 7 (77.8) |
| COMPLICATIONS | |||
| Graft rejection or suspicion | 7 (35.0) | 6 (54.5) | 1 (11.1) |
| Graft rejection | 3 (15.0) | 3 (27.3) | – |
| Suspicion with immunosuppressors treatment | 4 (20.0) | 3 (27.3) | 1 (11.1) |
| Glucocorticoids doses elevation or treatment | 7 (35.0) | 6 (54.5) | 1 (11.1) |
| Tacrolimus doses elevated | 1 (5.0) | 1 (9.1) | – |
| Infection post-transplant, n (%) | 14 (70.0) | 10 (90.9) | 4 (44.4) |
| Bacterial infection, n (%) | 7 (35.0) | 5 (45.5) | 2 (22.2) |
| Virus infections, n (%) | 9 (45.0) | 6 (54.5) | 3 (33.3) |
| CMV, n (%) | 4 (20.0) | 3 (27.2) | 1 (11.1) |
| EBV, n (%) | 7 (35.0) | 5 (45.5) | 2 (22.2) |
| Weigh gain post-transplant, n (%) | 9 (45.0) | 5 (45.5) | 4 (44.4) |
| Second renal transplant | 2 (10.0) | 2 (18.2) | – |
RT, Renal transplant; SDS, Standard deviation score; BMI, Body max index; LT, Liver transplant; PTLD, Post-Transplant Lymphoproliferative Disease; EBV, Epstein-Barr Virus; CMV, Cytomegalovirus.